Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Mallinckrodt
McKinsey
Merck
Johnson and Johnson

Last Updated: February 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Hypericin


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Hypericin?

Hypericin is an investigational drug.

There have been 5 clinical trials for Hypericin. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2016.

The most common disease conditions in clinical trials are HIV Infections, Lymphoma, and Hepatitis C. The leading clinical trial sponsors are National Institute of Allergy and Infectious Diseases (NIAID), VIMRx Pharmaceuticals, and University of Liverpool.

There is one US patent protecting this investigational drug and thirteen international patents.

Recent Clinical Trials for Hypericin
TitleSponsorPhase
Pilot Study on Intra-abdominal Photodynamic Diagnosis in Peritoneal CarcinosisUniversity Hospital TuebingenPhase 3
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)SoligenixPhase 3
Boceprevir and Ucalm (St John&Apos;s Wort)University of LiverpoolPhase 1

See all Hypericin clinical trials

Clinical Trial Summary for Hypericin

Top disease conditions for Hypericin
Top clinical trial sponsors for Hypericin

See all Hypericin clinical trials

US Patents for Hypericin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Hypericin   Start Trial Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC)   Start Trial
Hypericin   Start Trial Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders Dana-Farber Cancer Institute, Inc. (Boston, MA)   Start Trial
Hypericin   Start Trial Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Moodys
Boehringer Ingelheim
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.